Expertise in
7
conditions

Josee M. Zijlstra

Amsterdam, NH, NL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Josee Zijlstra practices in Amsterdam, Netherlands. Ms. Zijlstra is highly rated in 7 conditions, according to our data. Her top areas of expertise are Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 163 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Amsterdam, NH 1081HV, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drug: Tinostamustine
Study Phase: Phase 1
Molecular Imaging of Zirconium-89-labeled Atezolizumab as a Tool to Investigate Atezolizumab Biodistribution in High-risk Diffuse Large B-cell Lymphoma
Molecular Imaging of Zirconium-89-labeled Atezolizumab as a Tool to Investigate Atezolizumab Biodistribution in High-risk Diffuse Large B-cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 15, 2023
Intervention Type: Other
Study Phase: Not Applicable
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)
Enrollment Status: Unknown
Publish Date: March 13, 2018
Intervention Type: Drug, Other
Study Drugs: DHAP, Brentuximab Vedotin
Study Phase: Phase 1
View 3 Less Clinical Trials

162 Total Publications

Predicting Absolute Risk of First Relapse in Classical Hodgkin Lymphoma by Incorporating Contemporary Treatment Effects.
Predicting Absolute Risk of First Relapse in Classical Hodgkin Lymphoma by Incorporating Contemporary Treatment Effects.
Journal: Cancers
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Zijlstra's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile